Immune Signature of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin LymphomaBeatriz Wills, Alison J. Moskowitz, Gunjan L. Shah et al.|Blood|2022Cited by 0